REPERTOIRE GENESIS INCORPORATION;HYOGO COLLEGE OF MEDICINE
发明人:
MATSUMOTO, SEIJI,松本成司,SUZUKI, RYUJI,铃木隆二,鈴木隆二
申请号：
TW107108728
公开号：
TW201839128A
申请日:
2018.03.14
申请国别(地区):
TW
年份:
2018
代理人:
摘要：
The present invention provides a technique for predicting a responder prior to beginning cancer immunotherapy. The present invention provides a method for using the T cell receptor (TCR) diversity of a subject as an indicator of the responsiveness of the subject to cancer immunotherapy. The present invention also provides a composition including an immune checkpoint inhibitor, wherein the composition is for treating cancer in a subject having high TCR diversity of the T cells. The present invention also pertains to a companion drug in which such TCR diversity is used.本發明提供一種於開始癌症免疫療法之前預測有效患者之技術。本發明提供一種使用受驗體之T細胞受體(TCR)多樣性作為該受驗體對癌症免疫療法之應答性之指標的方法。又，本發明提供一種包含免疫檢查點抑制劑之組合物，其係用以對於T細胞之TCR多樣性高之受驗體治療癌症。又，本發明亦關於一種使用此種TCR多樣性之伴隨醫藥。
